[시장보고서]단클론항체 시장 규모, 점유율, 예측 및 동향 분석 : 제품 유형, 용도, 공급원, 생산 및 최종 사용자별

단클론항체 시장 규모, 점유율, 예측 및 동향 분석 : 제품 유형, 용도, 공급원, 생산 및 최종 사용자별 - 세계 예측(-2031년)

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type Application, Source, Production, End User - Global Forecast to 2031

상품코드 : 1504160

리서치사 : Meticulous Research

발행일 : On Demand Report

페이지 정보 : 영문 410 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,175

￦ 6,194,000

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.

US $ 5,875

￦ 8,716,000

PDF & Excel (Multi User License)

PDF & Excel 보고서를 동일 기업내 5명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 5부까지 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.

US $ 7,875

￦ 11,684,000

PDF & Excel (Global Site License)

PDF & Excel 보고서를 동일 기업 & 자회사의 모든 분이 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 단클론항체 시장은 2024-2031년간 11.2%의 연평균 복합 성장률(CAGR)로 2031년까지 4,498억 8,000만 달러에 달할 것으로 예측됩니다.

이 보고서는 광범위한 2차 및 1차 연구와 단클론항체 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 도전 과제 및 기회 분석으로 구성되어 있습니다. 단클론항체 시장의 성장은 전 세계 암 및 자가 면역 질환의 높은 부담, 임상시험 및 연구 자금 조달 증가, 바이오 제약 산업의 성장, 감염성 질환의 유병률 증가, 단백질체학 및 유전체학 연구 증가에 의해 주도되고 있습니다. 그러나 대체 진단 검사의 가용성, 항체 개발에 소요되는 높은 비용과 시간이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

또한, 제약 및 생명공학 기업의 R&D 투자 증가, 임상시험 및 의학 연구에서의 항체 적용 확대, 신흥국에서의 연구 활동 증가, 새로운 바이오마커 식별에 대한 수요 증가, 진단 검사 강화를 위한 노력 등이 시장 성장의 기회를 창출할 것으로 예상됩니다. 시장 성장 기회를 창출할 것으로 예상됩니다. 그러나 항체 검사의 낮은 정확도, 높은 제조 비용, 연구용 항체의 품질 및 안정성 문제, 제조 공정의 복잡성 등이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

개요
연구용 단클론항체
- 연구 영역
  - 종양학
  - 감염증
  - 순환기학
  - 면역학
  - 신경학
  - 줄기세포 연구
  - 기타 연구 분야
- 응용 분야
  - 단백질체학
  - Drug Discovery & Development
  - 유전체학
- 기술
  - 유세포분석기
  - 면역 형광법
  - 효소 결합 면역 흡착 측정법
  - 멀티플렉스 면역 흡착 어세이
  - 웨스턴 블롯팅
  - 면역조직화학
  - 면역 침강(IP)
  - 기타 연구 기술
진단용 단클론항체
- 용도
  - 종양학
  - 감염증
  - 임신 탐지/불임 검사
  - 심장 마커 검사
  - 기타 진단 용도
- 테크놀러지
  - ELISA법
  - 측면 흐름 분석
  - 면역조직화학(IHC)
  - 면역 침강(IP)
  - 웨스탄 블로팅(WB)
  - 면역 세포 화학(ICC)
  - 기타 진단 기술
치료용 단클론항체
- 치료 영역
  - 종양학
  - 자가면역질환
  - 신경질환
  - 감염증
  - 기타 치료 영역
- 투여 경로
  - 피하
  - 정맥내 투여

제6장 단클론항체 시장 : 제조 공정별 평가

개요
In Vivo 프로세스
In Vitro 프로세스
- Upstream 프로세스
- Downstream 프로세스

제7장 단클론항체 시장 : 공급원별 평가

개요
인간
인간화
마우스
키메라
기타 공급원

제8장 단클론항체 시장 : 최종사용자별 평가

개요
제약 기업 및 바이오테크놀러지 기업
병원
CRO(의약품 임상시험수탁기관)
기타 최종사용자

제9장 단클론항체 시장 : 지역별 평가

개요
북미
- 미국
- 캐나다
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 스위스
- 벨기에
- 기타 유럽(RoE)
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 기타 아시아태평양(RoAPAC)
라틴아메리카
- 브라질
- 멕시코
- 기타 라틴아메리카(RoLATAM)
중동 및 아프리카

제10장 경쟁 분석

개요
주요 성장 전략
경쟁 벤치마킹
경쟁 대시보드
- 업계 리더
- 시장 차별화 요인
- 선행 기업
- 신규 기업
주요 기업별 시장 점유율 분석/시장 순위(2023년)

제11장 기업 개요(기업 개요, 재무 개요, 제품 포트폴리오, 전략적 전개, SWOT 분석)

Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche AG
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb
GSK plc
Merck KGaA
Eli Lilly and Company
AstraZeneca plc
Johnson & Johnson
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company
Biogen
Thermo Fisher Scientific Inc.

(주 : 주요 5개사의 SWOT 분석을 게재)

제12장 부록

LSH

영문 목차

영문목차

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User-Global Forecast to 2031

The global monoclonal antibodies market is projected to reach $449.8 billion by 2031 at a CAGR of 11.2% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the monoclonal antibodies market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the monoclonal antibodies market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics. However, the availability of alternative diagnostic tests and the high costs & time required for antibody development restrain the market's growth.

Furthermore, increasing R&D investments by pharmaceutical & biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities. However, the inaccuracy of antibody tests, high manufacturing costs, concerns regarding the quality & stability of research antibodies, and complexities in the production process are some of the challenges impeding the market's growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Among the types covered in this report, in 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of over 90.2% of the monoclonal antibodies market. The therapeutic monoclonal antibodies segment is further sub-segmented into oncology, autoimmune diseases, neurological diseases, infectious diseases, and other therapeutic areas. The large market share of this segment is attributed to the increasing approvals for the therapeutical monoclonal antibodies, rising demand for biosimilars, increasing prevalence of target disease, technological advancements in the formulation of antibodies, an increasing number of pipeline products, and fewer side effects of monoclonal antibodies. Additionally, with the increasing prevalence of cancer, the demand for monoclonal antibodies is also increasing for personalized cancer therapies. According to GLOBOCAN, the prevalence of cancer is expected to increase by 63.4% in 2045 from 2022.

Among the production processes covered in this report, in 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. The in vitro segment is further segmented into upstream process and downstream process. The in vitro process scales up antibody production without reliance on animal models and animal testing. It increases the production of MABs and also mitigates the ethical concerns associated with the use of animals, thus preferred over the in vivo process.

Among the sources covered in this report, in 2024, the human segment is expected to account for the largest share of the monoclonal antibodies market. Human sources are preferred for the production of monoclonal antibodies to increase treatment efficiency by reducing the risk of immunogenicity or adverse immune response. Key players are also using human sources for the development of monoclonal antibodies to improve the safety profile of MABs, production of stable human hybridomas, and ease of scaling up production.

Among the end users covered in this report, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. The large market share of this segment is attributed to the availability of MAB therapies in hospitals, the increasing number of hospitals in emerging economies, and the launch of dedicated monoclonal antibody facilities by hospitals.

An in-depth analysis of the geographical scenario of the global monoclonal antibodies market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of over 34.9% of the monoclonal antibodies market. The largest share of the regional market is attributed to the presence of key players, availability of advanced antibody engineering technology, rising number of approvals, and supportive government initiatives for the development and use of monoclonal antibodies. For instance, in September 2023, the U.S. Department of Health and Human Services announced an initiative to give underinsured and uninsured Americans access to the COVID-19 monoclonal antibody treatment bebtelovimab even after the product availability in the commercial market.

Scope of the Report:

Monoclonal Antibodies Market Assessment-by Type

Research Monoclonal Antibodies
- Research Area
Oncology
Infectious Diseases
Cardiology
Immunology
Neurology
Stem Cell Research
Other Research Areas
- Application
Proteomics
Drug Discovery & Development
Genomics
- Technology
Flow Cytometry
Immunofluorescence
Enzyme-Linked Immunosorbent Assay
Multiplex Immunosorbent Assay
Western Blot
Immunohistochemistry
Immunoprecipitation (IP)
Other Research Technologies
Diagnostic Monoclonal Antibodies
- Application
Oncology
Infectious Diseases
Pregnancy Detection/Fertility Testing
Cardiac Marker Testing
Other Diagnostic Applications
- Technology
ELISA
Lateral Flow Assay
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Immunocytochemistry (ICC)
Other Diagnostic Technologies
Therapeutic Monoclonal Antibodies
- Therapeutic Area
Oncology
Autoimmune Diseases
Neurological Diseases
Infectious Diseases
Other Therapeutic Areas
- Route of Administration
Subcutaneous
Intravenous

Note: 1) Other Research Areas include Ophthalmology and Rare Diseases

2) Other Research Technologies include electrophoretic mobility shift assay (EMSA) and enzyme-linked immunospot (ELISPOT) assay

3) Other Diagnostic Applications include Alzheimer's, autoimmune diseases, cardiac diseases, and diabetes.

4) Other Diagnostic Technologies include Immunofluorescence, flow cytometry, in situ hybridization, dot blot, and radioimmunoassay.

5) Other Therapeutic Areas include cardiac diseases, diabetes, ophthalmology, and hematology

Monoclonal Antibodies Market Assessment-by Production Process

In Vivo Process
In Vitro Process
- Upstream Process
- Downstream Process

Monoclonal Antibodies Market Assessment-by Source

Human
Humanized
Murine
Chimeric
Other Sources

Note: Other Sources include goat, sheep, chicken, and llama

Monoclonal Antibodies Market Assessment-by End User

Pharmaceutical & Biotechnology Companies
Hospitals
Contract Research Organizations
Other End Users

Note: Other End Users include academic & research institutes, nursing centers, and long-term care centers

Monoclonal Antibodies Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Belgium
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. High Burden of Cancer and Autoimmune Diseases Globally
- 4.2.2. Increasing Funding for Clinical Trials and Research
- 4.2.3. Growth in the Biopharmaceutical Industry
- 4.2.4. Rising Proteomics and Genomics Research Studies
- 4.2.5. Rising Prevalence of Infectious Diseases
4.3. Restraints
- 4.3.1. Availability of Alternative Diagnostic Tests
- 4.3.2. High Costs & Time Required for Antibody Development
4.4. Opportunities
- 4.4.1. Expanding Applications of Antibodies in Clinical Trials and Medical Research
- 4.4.2 Increasing Research Activities in Developing Countries
- 4.4.3. Increasing Need for New Biomarker Identification
- 4.4.4. Initiatives Aimed at Enhancing Diagnostic Testing
- 4.4.5. Increasing R&D Investments by Pharmaceutical & Biotech Companies
4.5. Challenges
- 4.5.1. Inaccuracy of Antibody Tests
- 4.5.2. High Manufacturing Costs
- 4.5.3. Concerns Regarding the Quality & Stability of Research Antibodies
- 4.5.4. Complexities in the Production Process
4.6. Factor Analysis
4.7. Trends
- 4.7.1. Increasing Focus on Personalized Medicine
- 4.7.2. Advancements in Antibody Engineering
- 4.7.3. Integration of Artificial Intelligence in Monoclonal Antibody Production
- 4.7.4. Use of Humanized Mouse Models
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Pipeline Analysis
4.11. Porter's Five Force Analysis

5. Monoclonal Antibodies Market Assessment-by Type

5.1. Overview
5.2. Research Monoclonal Antibodies
- 5.2.1. Research Area
  - 5.2.1.1. Oncology
  - 5.2.1.2. Infectious Diseases
  - 5.2.1.3. Cardiology
  - 5.2.1.4. Immunology
  - 5.2.1.5. Neurology
  - 5.2.1.6. Stem Cell Research
  - 5.2.1.7. Other Research Areas
- 5.2.2. Application
  - 5.2.2.1. Proteomics
  - 5.2.2.2. Drug Discovery & Development
  - 5.2.2.3. Genomics
- 5.2.3. Technology
  - 5.2.3.1. Flow Cytometry
  - 5.2.3.2. Immunofluorescence
  - 5.2.3.3. Enzyme-Linked Immunosorbent Assay
  - 5.2.3.4. Multiplex Immunosorbent Assay
  - 5.2.3.5. Western Blot
  - 5.2.3.6. Immunohistochemistry
  - 5.2.3.7. Immunoprecipitation (IP)
  - 5.2.3.8. Other Research Technologies
5.3. Diagnostic Monoclonal Antibodies
- 5.3.1. Application
  - 5.3.1.1. Oncology
  - 5.3.1.2. Infectious Diseases
  - 5.3.1.3. Pregnancy Detection/Fertility Testing
  - 5.3.1.4. Cardiac Marker Testing
  - 5.3.1.5. Other Diagnostic Applications
- 5.3.2. Technology
  - 5.3.2.1. ELISA
  - 5.3.2.2. Lateral Flow Assay
  - 5.3.2.3. Immunohistochemistry (IHC)
  - 5.3.2.4. Immunoprecipitation (IP)
  - 5.3.2.5. Western Blot (WB)
  - 5.3.2.6. Immunocytochemistry (ICC)
  - 5.3.2.7. Other Diagnostic Technologies
5.4. Therapeutic Monoclonal Antibodies
- 5.4.1. Therapeutic Area
  - 5.4.1.1. Oncology
  - 5.4.1.2. Autoimmune Diseases
  - 5.4.1.3. Neurological Diseases
  - 5.4.1.4. Infectious Diseases
  - 5.4.1.5. Other Therapeutic Areas
- 5.4.2. Route of Administration
  - 5.4.2.1. Subcutaneous
  - 5.4.2.2. Intravenous

6. Monoclonal Antibodies Market Assessment-by Production Process

6.1. Overview
6.2. In Vivo Process
6.3. In Vitro Process
- 6.3.1. Upstream Process
- 6.3.2. Downstream Process

7. Monoclonal Antibodies Market Assessment-by Source

7.1. Overview
7.2. Human
7.3. Humanized
7.4. Murine
7.5. Chimeric
7.6. Other Sources

8. Monoclonal Antibodies Market Assessment-by End User

8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Hospitals
8.4. Contract Research Organizations (CROs)
8.5. Other End Users

9. Monoclonal Antibodies Market Assessment-by Geography

9.1. Overview
9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Switzerland
- 9.3.7. Belgium
- 9.3.8. Rest of Europe (RoE)
9.4. Asia-Pacific
- 9.4.1. Japan
- 9.4.2. China
- 9.4.3. India
- 9.4.4. South Korea
- 9.4.5. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America (RoLATAM)
9.6. Middle East & Africa

10. Competition Analysis

10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Ranking, by Key Players (2023)

11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)

11.1. Novartis AG
11.2. Pfizer Inc.
11.3. F. Hoffmann-La Roche AG
11.4. AbbVie Inc.
11.5. Amgen Inc.
11.6. Bristol-Myers Squibb
11.7. GSK plc
11.8. Merck KGaA
11.9. Eli Lilly and Company
11.10. AstraZeneca plc
11.11 Johnson & Johnson
11.12. Takeda Pharmaceutical Company Limited
11.13. Daiichi Sankyo Company
11.14. Biogen
11.15. Thermo Fisher Scientific Inc.

(Note: SWOT analysis of the top 5 companies will be provided.)

12. Appendix

12.1. Available Customization
12.2. Related Reports